Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

Kyungsoo Ha, Warren Fiskus, Dong Soon Choi, Srividya Bhaskara, Leandro Cerchietti, Santhana G.T. Devaraj, Bhavin Shah, Sunil Sharma, Jenny C. Chang, Ari M. Melnick, Scott Hiebert, Kapil N. Bhalla

Research output: Contribution to journalArticle

85 Scopus citations

Abstract

There is an unmet need to develop new, more effective and safe therapies for the aggressive forms of triple negative breast cancers (TNBCs). While up to 20% of women under 50 years of age with TNBC harbor germline mutations in BRCA1, and these tumors are sensitive to treatment with poly(ADP) ribose polymerase inhibitors, a majority of TNBCs lack BRCA1 mutations or loss of expression. Findings presented here demonstrate that by attenuating the levels of DNA damage response and homologous recombination proteins, pan-histone deacetylase inhibitor (HDI) treatment induces 'BRCAness' and sensitizes TNBC cells lacking BRCA1 to lethal effects of PARP inhibitor or cisplatin. Treatment with HDI also induced hyperacetylation of nuclear hsp90. Similar effects were observed following shRNA-mediated depletion of HDAC3, confirming its role as the deacetylase for nuclear HSP90. Furthermore, cotreatment with HDI and ABT-888 induced significantly more DNA strand breaks than either agent alone, and synergistically induced apoptosis of TNBC cells. Notably, co-treatment with HDI and ABT-888 significantly reduced in vivo tumor growth and markedly improved the survival of mice bearing TNBC cell xenografts. These findings support the rationale to interrogate the clinical activity of this novel combination against human TNBC, irrespective of its expression of mutant BRCA1.

Original languageEnglish (US)
Pages (from-to)5637-5650
Number of pages14
JournalOncotarget
Volume5
Issue number14
DOIs
StatePublished - 2014

Keywords

  • BRCAness
  • HDAC inhibitor
  • PARP inhibitor
  • Triple Negative Breast Cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells'. Together they form a unique fingerprint.

Cite this